A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

NCT07477548 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Vascular Malformations
Arteriovenous Malformations
Venous Malformation
Lymphangioma
Nevus, Port-Wine
Hemangioendothelioma
Hemangioma

Interventions

DRUG: Everolimus

Sponsor

Yonsei University